Global Digital Migraine Treatment Device Market is segmented By Type (Supraorbital Stimulation Digital Migraine Treatment Devices, Vagus Nerve Stimulation Digital Migraine Treatment Devices (VNS), Single-pulse Transcranial Magnetic Stimulation Digital Migraine Treatment Devices (sTMS), Occipital Nerve Stimulation Digital Migraine Treatment Devices (ONS), Others), By Application (Hospitals, Specialty Clinics, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Market Overview
The global digital migraine treatment device market is estimated to reach at a high CAGR during the forecast period (2022-2029).
Migraine is a neurological condition that can cause multiple symptoms. Intense, debilitating headaches frequently characterize it. The treatment uses electrical stimulation that targets the vagus nerve in the neck.
Market Dynamics
The increasing number of non-invasive neurostimulator devices for treating migraines is expected to drive the market's growth.
According to the Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM), in 2020. The first non-invasive neurostimulator device approved for migraine treatment was the Cefaly device, an external trigeminal nerve stimulation device (e-TNS) that transcutaneously triggers the supratrochlear supraorbital branches of the ophthalmic nerve. The second non-invasive neurostimulation device securing FDA approval was the single-pulse transcranial magnetic stimulator, SpringTMS, located at the occiput to treat migraine with aura. Moreover, gammaCore is a handheld transcutaneous vagal nerve stimulator applied directly to the neck at home by the patient to treat cluster headache (CH) and migraine. Several other devices are in development to treat headaches and target headache evolution at different levels and inputs. Thus, from the above statements, the increasing number of non-invasive neurostimulator devices for treating migraines is expected to drive the market's growth.
The increasing prevalence of migraines is expected to drive the market's growth.
A migraine is a headache that causes severe throbbing pain, normally on one side of the head. It's often accompanied by nausea, vomiting, and severe sensitivity to light and sound, and migraine attacks can last for hours to days. The pain can be so sharp that it interferes with your daily activities. Moreover, it affects children and teenagers and adults and can grow through four stages: prodrome, aura, attack, and post-drome. According to the article (Research gate), not everyone who has migraines goes through all stages (Research gate), published on April 8, 2021. The prevalence of migraines was 18.2% among females and 6.5% among males—approximately 23% of households contained at least one member suffering from migraines. Migraine prevalence is higher in whites than in blacks and was inversely related to household income. Thus, a rise in the prevalence of migraine cases leads to increased demand for migraine treatment devices.
Increasing inpatients in hospitals associated with the high cost are expected to hamper the growth of the market.
According to the Journal(PRS), in 2020. Migraine headache is associated with high costs, but changes over time of inpatient burden in the United States are unknown. Data from the Nationwide Inpatient Sample of the Hospitalization Cost and Utilization Project databases are analyzed from 1997 to 2012. Inpatient costs were reported in dollars for the cost to the institution, whereas charges reflect the amount billed. These parameters are trended, and the average annual percent change is calculated to illustrate year-to-year changes. Overall discharges for migraine headaches reached a low of 30,761 discharges in 1999 and peaked in 2012 with 54,510 discharges. The average length of stay decreased from 3.5 days in 1997 to 2.8 days in 2012.
Additionally, inpatient burden rapidly increased over the analyzed period, with hospital charges increasing from $5,939 per admission and $176 million nationwide in 1997 to $21,576 per admission and $1.2 billion nationwide in 2012. Hence, from the above statements, the increasing inpatients in hospitals associated with the high cost are expected to hamper the market's growth.
Digital Migraine Treatment Device Market Industry Analysis
COVID-19 Impact Analysis
The coronavirus disease 2019 (COVID-19) pandemic has caused overwhelming challenges in healthcare worldwide. Migraine is one of the commonest and extremely disabling chronic neurological diseases in the world. During the pandemic and lockdown, migraine patients face an immense problem in getting maximum care because of difficulty in admittance, forced social isolation, and encountering a health system that is getting overwhelmed. Moreover, in the absence of therapeutic procedures, other preventive therapies such as self-injectable monoclonal antibodies, neuromodulation devices and oral corticosteroids are used. The patients must be protected by reducing their visits to the clinics and emergency departments. Moreover, paradoxically multiple triggers are in operation, which is likely to increase their headache frequency. Hence, physicians should be made aware of the game's new rules in handling migraines during this time of the pandemic so that these patients get maximum treatment and care and don't feel left out.
The pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period..
Segment Analysis
Single-pulse Transcranial Magnetic Stimulation Digital Migraine Treatment Devices (sTMS) segment is expected to hold the largest market share in this market segment.
The single-pulse transcranial magnetic stimulation digital migraine treatment devices (sTMS) segment held the largest market share in 2020. It is benefited because of its potential, preventive and acute treatment for migraine. It can be administered at home by placing the sTMS device against the back of your head and activating it. The device delivers a short magnetic pulse that targets the layers of the scalp, the skull, the meninges (membranes that enclose the brain and spinal cord), the cerebrospinal fluid, and the superficial layers of the cortex, where it modulates the electrical environment of neurons involved in migraine attacks. For instance, according to the article, on March 2, 2021. The eNeura sTMS mini is an FDA-approved sTMS device previously sold under the brand name Spring TMS. It’s a battery-powered handheld device that is used to prevent and treat migraine attacks. Hence, from the above statements, the digital migraine treatment device market is expected to boost in the forecast period.
Geographical Analysis
North America region holds the largest market share in the global digital migraine treatment device Market.
North America dominated the market with a revenue share in 2020. The growth is attributed to the presence of well-established healthcare infrastructure and the increasing R&D funding. Raising peripheral neuromodulation for the management of headaches is expected to boost the market in the forecast period. For instance, according to the Anesthesiology and Pain Medicine, in 2020. Neuromodulation is an inflate field of study for headache treatment to reduce pain by targeting structures within the nervous system commonly involved in headache pathophysiologies, such as the vagus nerve (VNS) and sphenopalatine ganglion (SPG) for stimulation. Additionally, pharmaceutical therapies for abortive and prophylactic treatment, such as triptans, NSAIDs, beta-blockers, TCAs, and antiepileptics, are effective for some individuals.
Peripheral neuromodulation has grown popularity and FDA approval for treating certain headaches and migraine headache conditions, especially in those that are hard to treat. Moreover, early trials found FDA-approved neurostimulatory implant devices, including Cephaly and SpringTMS, improved patient-oriented outcomes with reductions in headaches per month (frequency) and severity. Hence, from the above statements, the North American region holds the largest market share.
Competitive Landscape
The digital migraine treatment device market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Cefaly Technology, Cirrus Healthcare Products, ElectroCore, Inc., eNeura Inc., Neurolief Ltd., Neuros Medical, Prolivio, Relivion, Salvia BioElectronics and Theranica Bio-Electronics LTD. The major players are adopting several growth strategies such as Type launches, acquisitions, and collaborations, which are contributing to the growth of the digital migraine treatment device market globally.
Digital Migraine Treatment Device Market Key Companies to Watch
Cefaly Technology:
Overview:
Cefaly Technology was established in 2008; it is into wearable medical devices clinically proven to help reduce migraine frequency and relieve migraine pain.
Type Portfolio:
Cefaly Technology is into the continuous offering of CEFALY DUAL, which is FDA Cleared/CE Marked for the abortive and preventative treatment of migraine, effective with drug-free treatment.
Key Development:
On June 8, 2021, announced the launch of CeCe, the comprehensive, easy-to-use migraine management mobile app that helps users better understand life with migraine, now available as a free download for iOS and Android.
The global digital migraine treatment device market report would provide an access to an approx.47 market data table, 42 figures and 200pages.
